Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wellgistics Health, Inc. (NASDAQ: WGRX) SEC filings page on Stock Titan brings together the company’s official disclosures to U.S. regulators, including current reports on Form 8-K, quarterly reports on Form 10-Q, and related exhibits. These documents provide detail on Wellgistics Health’s operations as a pharmacy physical and technology enabling health IT company that connects more than 6,500 pharmacies and over 200 manufacturers through wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Through its filings, Wellgistics has reported material events such as the license agreement with DataVault AI Inc. for intellectual property used to develop its PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts platform, sponsorship and licensing arrangements related to Dream Bowl 2026, and debt conversion agreements. Filings also describe the launch and positioning of the EinsteinRx™ pharmacy dispensing optimization AI platform, changes in independent registered public accounting firms, and the reporting of quarterly financial results.
Investors can also review an 8-K describing a Nasdaq notice regarding the company’s minimum bid price deficiency and the associated compliance period, which outlines potential implications for the continued listing of WGRX on The Nasdaq Capital Market. These regulatory documents offer insight into governance, capital structure, strategic partnerships, and risk factors referenced in the company’s public communications.
On Stock Titan, SEC filings for WGRX are supplemented with AI-powered summaries that highlight key terms, financial metrics, and business developments from lengthy documents. Users can quickly identify items related to licensing arrangements, sponsorship agreements, auditor changes, and listing compliance, while still having access to the full text as filed with the SEC. The page also provides convenient access to forms associated with insider and shareholder-related activity when available, helping users track how Wellgistics Health’s regulatory profile evolves over time.
Wellgistics Health, Inc. director Surendra K. Ajjarapu received a large equity compensation package. On March 31, 2026, he was granted 5,000,000 shares of common stock at a stated value of $0.20 per share, bringing his direct holdings to 7,882,247 shares.
He was also granted 5,000,000 warrants to purchase common stock at an exercise price of $0.01 per share, expiring on March 31, 2031. The footnotes state both the shares and warrants were issued as compensation for his service in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Wellgistics Health, Inc. filed an amended report describing a new joint venture with Kare Pharmtech affiliates and a Nasdaq listing deficiency notice. The company agreed to form Healthstar Technologies, LLC, holding a 51% membership interest while Kare Rx Hub holds 49%.
In exchange for Kare Rx Hub transferring certain intellectual property and related assets to Healthstar, Wellgistics will pay Kare Pharmtech $2,000,000 in common stock, including 1,500,000 shares at closing and potential additional shares by April 1, 2027, based on a two-day volume-weighted average price. These unregistered shares will be restricted and subject to a 12‑month lock-up. Closing is conditioned on satisfactory due diligence, with either side able to terminate if dissatisfied.
Separately, Nasdaq notified Wellgistics that it is not in compliance with Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity. The company reported stockholders’ equity of $(12,447,801) and also does not meet alternative continued listing standards. Wellgistics has until May 28, 2026 to submit a compliance plan and may receive up to 180 days from April 13, 2026 to regain compliance if Nasdaq accepts that plan.
Wellgistics Health, Inc. entered into a Collaboration Agreement to form a new limited liability company, Healthstar, with Kare Rx Hub, LLC. Wellgistics will hold a 51% membership interest and Kare Hub will hold 49%. Kare Hub will transfer specified intellectual property and related assets into Healthstar.
As consideration, Wellgistics agreed to pay Kare Pharmtech an aggregate purchase price of $2,000,000 in unregistered common stock. The agreement provides for 1,500,000 shares at closing and, at Wellgistics’ option, additional shares by April 1, 2027, based on a two-day volume-weighted average price. The Purchase Shares will be restricted, with Kare Pharmtech subject to a 12‑month lock-up from each payment date.
A related press release explains that the joint venture combines Wellgistics’ EinsteinRx™ and HubRx AI™ platforms with KareRx’s digital hub, creating an integrated ecosystem that can potentially reach more than 200,000 patient lives and support direct‑to‑patient and decentralized care models.
Wellgistics Health, Inc. filed a shelf registration to offer up to $200,000,000 of securities, including Common Stock, Preferred Stock, Debt Securities, Warrants, Rights and Units, to be sold from time to time.
The prospectus states the offering is on a shelf basis under Rule 415 and that proceeds are intended for general corporate purposes, including product development, R&D, licensing, capital expenditures and working capital. The prospectus discloses 126,653,372 shares issued and outstanding as of April 10, 2026 and a reported Nasdaq closing price of $0.1441 per share on April 14, 2026.
Wellgistics Health, Inc. director Herman Gary L filed an initial Form 3, which is a statement of his beneficial ownership of company securities. This filing does not list any stock purchases, sales, or option exercises, and instead establishes his status as an insider for future ownership reporting.
Wellgistics Health, Inc. director Eric Michael Sherb has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The filing reports no transactions and does not show any specific share or option holdings in the provided data.
Wellgistics Health, Inc. terminated a prior Settlement Agreement with Silverback Capital Inc. that had allowed it to issue common stock under Section 3(a)(10) of the Securities Act. Before termination, the company issued 6,866,000 shares under this structure. The agreement is no longer in effect, no additional shares will be issued under it, and Silverback has been asked to return all rights to unpaid claims to the relevant creditors. Wellgistics elected to end this settlement structure to pursue alternative strategic and financing initiatives, which the company states eliminates potential future dilution tied to the Settlement Agreement.
Wellgistics Health, Inc. entered into a Note Purchase Agreement on April 1, 2026 to issue and sell up to $1,250,000 in aggregate principal amount of promissory notes in a private offering. Investors will pay $1,000,000, reflecting a 20% original issue discount.
The Notes bear 0% interest unless an event of default occurs, in which case interest increases to 15% per year. All principal and any default interest are due on the earlier of 12 months from issuance or the closing of a Qualified Financing. While the notes are outstanding, the company has agreed not to incur additional borrowed money debt or grant new liens, and investors receive the right to participate in future securities offerings up to 100% of their note principal.
Wellgistics Health, Inc. has notified stockholders that holders of a majority of its outstanding common stock approved, by written consent, a board-authorized reverse stock split at a ratio between 1-for-25 and 1-for-200, exercisable at the Board's discretion within 12 months of the written consent.
The action was approved by holders representing 66,590,104 votes (approximately 55.32%) of the 120,380,108 shares issued and outstanding as of April 1, 2026. The company will mail this Information Statement on or about April 3, 2026. The Board may file the amendment to effect a reverse split at any time before the end of the 12-month period or decide not to proceed.
Wellgistics Health, Inc. director Marlene Velez has filed an initial Form 3, which is a required statement of her beneficial ownership position in the company’s securities. The filing shows no reported purchases, sales, option exercises, gifts, or other transactions at this time.